Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 7/20 | 0.49 |
| ▸ | CSF1R | P07333 | 10/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FRK | P42685 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313087 | 1.00 | AURKA (0.52) | AURKAAURKBCCNT1CDK9GPR55 | |
| SCHEMBL3557473 | 1.00 | AURKA (0.52) | AURKAAURKBCCNT1CDK9GPR55 | |
| SCHEMBL1679263 | 0.86 | CSF1R (0.59) | AURKAAURKBCCNT1CDK9GPR55 | |
| SCHEMBL14705857 | 0.85 | CSF1R (0.48) | AURKAAURKBCSF1RRETPDGFRB | |
| SCHEMBL13478835 | 0.85 | CSF1R (0.48) | AURKAAURKBCCNT1CDK9CSF1R | |
| SCHEMBL6528042 | 0.85 | CSF1R (0.53) | AURKAAURKBCCNT1CDK9CSF1R | |
| SCHEMBL3149272 | 0.85 | CSF1R (0.53) | AURKAAURKBCCNT1CDK9CSF1R | |
| SCHEMBL1678955 | 0.84 | CSF1R (0.62) | CCNT1CDK9CSF1RRETPDGFRB | |
| SCHEMBL1679576 | 0.84 | CSF1R (0.62) | CCNT1CDK9CSF1RRETPDGFRB | |
| SCHEMBL1991252 | 0.84 | CSF1R (0.62) | CCNT1CDK9CSF1RRETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689739-B1 | AZOLE-BASED KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-03-30 | — | — | EP | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010148351-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-7737143-B2 | Substituted pyrazines as kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-06-15 | — | — | US | disclosed |
| US-7737143-B2 | Substituted pyrazines as kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-06-15 | — | — | US | disclosed |
| US-7737143-B2 | Substituted pyrazines as kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-06-15 | — | — | US | disclosed |
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | PRKACA, MAP3K6, PRKDC | AURKA 486/4885AURKB 837/4885CCNT1 809/4885 |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | AURKA 390/4885AURKB 426/4885CCNT1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.